Erasca Highlights 8–21× CYPA Binding Advantage and 10× Dose Reduction
Erasca reported ERAS-0015 binds CYPA with 8–21× higher affinity than RMC-6236, enabling comparable tumor regression at one-tenth to one-fifth the dose in preclinical models. Both programs are on track for H1 2026 safety, PK and efficacy from AURORAS-1 and H2 2026 updates from BOREALIS-1, with dose-expansion and combination arms into 2027.
1. ERAS-0015 Preclinical and Early Clinical Highlights
ERAS-0015 exhibits 8–21× higher CYPA binding affinity versus RMC-6236, driving comparable tumor regression in preclinical models at just one-tenth to one-fifth of the dose. Early Phase 1 data demonstrate multiple responses at 8 mg once daily, linear pharmacokinetics below 40 mg and predominantly low-grade adverse events without dose-limiting toxicities.
2. Clinical Timeline and Milestones
The AURORAS-1 dose-escalation trial is enrolling rapidly and remains on track for a first-half 2026 update covering safety, pharmacokinetics and efficacy in dozens of patients. The BOREALIS-1 study of ERAS-4001 will deliver a second-half 2026 data update, positioning the program for 2027 dose-expansion and combination work.
3. ERAS-4001 Profile and Combination Strategy
ERAS-4001 is a switch-II pocket, reversible pan-KRAS inhibitor with single-digit nanomolar potency against key mutations and a distinct scaffold to avoid known liabilities. Erasca plans to test pan-RAS and anti-EGFR combinations in colorectal cancer to assess tolerability and may pursue KRAS-selective approaches if broader RAS inhibition limits combination options.